The needs of patients are central to our company. Hence, AMW has concentrated on the development of highly active application-optimised drug products.
A vast majority of modern drug substances, i.e. peptides and proteins, are not appropriate for oral or transdermal use. These molecules, which are either too big or too little lipophilic to be absorbed through intact skin or mucous membranes, are digested upon oral application. In these cases subdermal drug delivery systems, made as biodegradable implants, may be developed to exhibit similar advantages concerning comfort, compliance, continuous drug release, and reduced side effects, as transdermal systems. A further advantage is the less frequent application e.g. monthly or even biannual injection.
Implants are 10 to 20 mm long polymer rods with diameters of 1 to 2 mm and enclose small amounts of highly active drug substances. Physicians inject implants by means of a specially designed injection device. The injector is engineered to help the doctor avoiding misapplication or painful application. Once injected, the implants take up water from the subcutaneous tissues, swell, form a gel, and are degraded to nontoxic compounds like lactic acid. The degradation process is accompanied by a predefined permanent drug release, adjusted to the duration and extent of the release rate necessary for an efficient therapy.
The availability of highly active compounds is a vital prerequisite for the development of implants, because the size of one unit is limited. The creativity of the formulation scientists at AMW consists in finding and optimising the composition of suitable polymers to result in formulations that release the drug substances in time periods between one and six months.
Next to advancing its proprietary pipeline, AMW remains in constant contact with innovative pharmaceutical and MedTech companies regarding new transdermal and/or parenteral drug delivery systems. In order to help prevent generic competition for these companies, we develop minimizing the risk of failure and with the goal of patent extensions to increase the lucrativeness of the products. AMW's policy is to license out such products under the precondition that AMW is also the manufacturer.